Advertisement

Handbook of Anticancer Pharmacokinetics and Pharmacodynamics

  • William D. Figg
  • Howard L. McLeod

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Udai Banerji, Ian Judson, Paul Workman
    Pages 1-27
  3. Angelika M. Burger, Heinz-Herbert Fiebig
    Pages 29-44
  4. Edward A. Sausville, Melinda Hollingshead
    Pages 45-55
  5. Howard Gurney
    Pages 57-73
  6. James Cassidy
    Pages 75-80
  7. Hans Ehrsson, Staffan Eksborg, Jonas Bergh
    Pages 81-90
  8. Andrew P. Beelen, Lionel D. Lewis
    Pages 111-127
  9. Sharyn D. Baker, Michelle A. Rudek
    Pages 129-137
  10. Kenneth S. Bauer, William P. Petros
    Pages 139-148
  11. Paul J. Williams, James A. Uchizono, Ene I. Ette
    Pages 149-167
  12. Alex Sparreboom, Walter J. Loos
    Pages 169-188
  13. Sally A. Coulthard, Alan V. Boddy
    Pages 189-213
  14. Yuichi Ando
    Pages 215-229
  15. Jan Stoehlmacher, Syma Iqbal, Heinz-Josef Lenz
    Pages 231-243
  16. Laurent P. Rivory
    Pages 245-266
  17. Susan E. Bates, Tito Fojo
    Pages 267-288
  18. Jeff Stone, Susan M. Blaney
    Pages 289-306
  19. H. Richard Alexander, Maihgan A. Kavanagh, Steven K. Libutti, James F. Pingpank
    Pages 327-348
  20. Steve Y. Cho, Howard A. Fine
    Pages 373-393
  21. Lisa C. Iacono, P. Kellie Turner, Clinton F. Stewart
    Pages 395-419
  22. Patricia W. Slattum, Jürgen Venitz
    Pages 421-430
  23. H. Trent Spencer, Jacques Galipeau
    Pages 439-456
  24. Philip M. Arlen, James Gulley, Lauretta Odogwu, John L. Marshall
    Pages 457-473
  25. Victor Ghetie, E. Sally Ward, Ellen S. Vitetta
    Pages 475-498
  26. Håkan Mellstedt, Jan-Erik Frödin, Anders Österborg
    Pages 499-522
  27. Thomas G. Roberts Jr., Thomas J. Lynch Jr., Bruce A. Chabner
    Pages 539-578
  28. Jill M. Kolesar
    Pages 593-611
  29. Back Matter
    Pages 613-623

About this book

Introduction

There are many steps on the road from discovery of an anticancer drug to securing its final approval by the U. S. Food and Drug Administration (FDA). In Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes that lead to anticancer drugs, creating a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. They detail each step in the process, ranging from compound design and synthesis, screening techniques using in vitro models, and SAR analysis for lead optimization, to in vivo experiments, formulation, preclinical pharmacokinetics, formal toxicology, and phase I, II, and III trials. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique road map for moving an agent to NDA submission.
Comprehensive and highly practical, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics provides in one volume a detailed step-by-step guide to the successful design and approval of anticancer drugs.

Keywords

DNA angiogenesis cancer clinical trial cytochrome P450 drug discovery drug resistance gene therapy kinetics pharmacodynamics pharmacokinetics pharmacology radiotherapy screening vaccine

Editors and affiliations

  • William D. Figg
    • 1
  • Howard L. McLeod
    • 2
  1. 1.Center for Cancer ResearchNational Cancer InstituteBethesdaUSA
  2. 2.Washington University School of MedicineSt. LouisUSA

Bibliographic information